Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)

This publication has 26 references indexed in Scilit:

• Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  JAMA, 2002
• Inhibition of Neointima by Angiotensin-Converting Enzyme Inhibitor in Porcine Coronary Artery Balloon-Injury Model
  Hypertension, 2001
• Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction
  European Heart Journal, 2000
• Acute anti–ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function
  The American Journal of Cardiology, 1999
• Lifetime risk of developing coronary heart disease
  The Lancet, 1999
• Perindopril Reduces Blood Pressure but Not Cerebral Blood Flow in Patients With Recent Cerebral Ischemic Stroke
  Stroke, 1997
• A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction
  New England Journal of Medicine, 1995
• Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.
  Journal of Clinical Investigation, 1995
• Dose-dependent effects of perindopril on blood pressure and small-artery structure.
  Hypertension, 1994
• Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
  The Lancet, 1992